GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyell Immunopharma Inc (NAS:LYEL) » Definitions » Scaled Net Operating Assets

Lyell Immunopharma (Lyell Immunopharma) Scaled Net Operating Assets : 0.22 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Lyell Immunopharma Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Lyell Immunopharma's operating assets for the quarter that ended in Dec. 2023 was $203.81 Mil. Lyell Immunopharma's operating liabilities for the quarter that ended in Dec. 2023 was $31.91 Mil. Lyell Immunopharma's Total Assets for the quarter that ended in Sep. 2023 was $794.99 Mil. Therefore, Lyell Immunopharma's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.22.


Lyell Immunopharma Scaled Net Operating Assets Historical Data

The historical data trend for Lyell Immunopharma's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lyell Immunopharma Scaled Net Operating Assets Chart

Lyell Immunopharma Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
- 0.29 0.42 0.23 0.18

Lyell Immunopharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 0.25 0.23 0.22 0.22

Competitive Comparison of Lyell Immunopharma's Scaled Net Operating Assets

For the Biotechnology subindustry, Lyell Immunopharma's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lyell Immunopharma's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyell Immunopharma's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Lyell Immunopharma's Scaled Net Operating Assets falls into.



Lyell Immunopharma Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Lyell Immunopharma's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(203.806-31.91)/937.561
=0.18

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=750.029 - 546.223
=203.806

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=95.077 - 56.894 - 6.273
=31.91

Lyell Immunopharma's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Dec. 2023 )
=(Operating Assets (Q: Dec. 2023 )-Operating Liabilities (Q: Dec. 2023 ))/Total Assets (Q: Sep. 2023 )
=(203.806-31.91)/794.989
=0.22

where

Operating Assets(Q: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=750.029 - 546.223
=203.806

Operating Liabilities(Q: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=95.077 - 56.894 - 6.273
=31.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lyell Immunopharma Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Lyell Immunopharma's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Lyell Immunopharma (Lyell Immunopharma) Business Description

Traded in Other Exchanges
N/A
Address
201 Haskins Way, South San Francisco, CA, USA, 94080
Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors).
Executives
Richard Klausner director, officer: Executive Chairman 5200 ILLUMINA WAY, SAN DIEGO CA 92122
Matthew Lang officer: Chief Business Officer C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Rahsaan Thompson officer: Chief Legal Officer 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Tina M. Albertson officer: Chief Medical Officer C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO CA 94080
Gary K. Lee officer: Chief Scientific Officer C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO CA 94080
Cathy Friedman director C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Arch Venture Fund Ix Overage, L.p. 10 percent owner 8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631
Elizabeth Homans director, officer: Chief Executive Officer C/O LYELL IMMUNOPHARMA, INC., 400 EAST JAMIE COURT, SUITE 301, SOUTH SAN FRANCISCO CA 94080
Stephen J. Hill officer: Chief Technical Ops. Officer C/O LYELL IMMUNOPHARMA, INC., 400 EAST JAMIE COURT, SUITE 301, SOUTH SAN FRANCISCO CA 94080
Charles W. Newton officer: Chief Financial Officer 46 FREDRICK AVENUE, ATHERTON CA 94027
Otis W Brawley director 5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Elizabeth G Nabel director BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115
William Jl Rieflin director NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Arch Venture Partners Ix, Llc 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Ix, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631